The Future of Drug Discovery - Who Decides Which Diseases to Treat?

Informationen zum Autor Tamas Bartfai was a student of mathematics, physics, and chemistry before translating his skills into biochemistry, pharmacology and neuroscience. Trained in Stockholm University, Yale University, and The Rockefeller University, he is presently a professor at The Scripps Research Institute, the University Oxford, and the University of Pennsylvania, and an expert in medicinal chemistry and the neurological sciences. He has been working in the development of new medicines and vaccines for many years as a former Sr.VP of Hoffmann La Roche, and long-term consultant at Astra, Novartis and, presently, Pfizer. Eight of the drugs Dr. Bartfai developed are in clinical use and three are in trials. He has trained and collaborated with many scientists throughout his scientific work on the topics of fever, neuropeptides, and prostaglandins, while publishing over 400 articles in over 80 journals. Dr. Bartfai has held many prestigious academic positions. He is a member of Academia Europae and the Hungarian Academy of Sciences, a fellow of AAAS for pioneering work on neuropeptides, and a member of the Royal Swedish Academy of Sciences, which awards the Nobel Prizes in Chemistry and Physics. He was professor of the Karolinska Institute, which awards the Nobel Prize in Medicine or Physiology. He has been awarded a number of prestigious prizes including Eötvös Medal for mathematics in 1966, Budapest, Hungary; Royal Swedish Academy’s Svedberg Prize for biochemistry in 1985 and Ericsson Prize in 1996; and the Ellison Medical Foundation Senior Scholar Award 2002. Graham V Lees acquired his BA, MA and PhD degrees at the University of Cambridge. His postdoctoral work on the biophysics of ion channels was followed by a lengthy career in scientific, technical and medical publishing with Elsevier (Amsterdam), Raven Press (New York), Academic Press (San Diego & London) and TheScientificWorld (San Diego, Boynton Beach, Newbury & Helsinki). His scientific writing has been actively increasing, including contributions to the textbook Fundamental Neuroscience; co-editing with Edward G. Jones and Lorne Mendell, and contributing to Neuroscience to Neurological Recovery for the Society for Neuroscience (SfN); and co-authoring The Future of Drug Discovery: Who Decides Which Diseases to Treat and Drug Discovery: From Bedside to Wall Street with Tamas Bartfai. He is interested in politics and social aspects of drug discovery. He has a profound ability to translate complex processes and ideas into more simple English that can be widely read. The authors’ previous book Drug Discovery: from Bedside to Wall Street, Elsevier/Academic Press, 2006, has been published in Japanese (Chem-Bio Informatics Society) and Mandarin (Science Press). Their later book’s Japanese and Mandarin editions are in preparation. Klappentext The authors posit that as a result of increasing risk aversion and accelerated savings in R&D over the past 3 years, the industry is not developing drugs for increasingly prevalent diseases, untreatable pain, antibiotics and more. The Future of Drug Discovery exposes the disconnect between what society needs and what pharmaceutical companies are working on. Entire drug development programs have been cancelled and incentives are needed for the pharmaceutical industry to change its current research and business path. This thought-provoking book analyzes the situation, projects over 10 years into the future and aids the reader in determining what is needed to ensure that the industry responds to society¿s needs while remaining commercially attractive. Suitable for all those who care about the development needs for drugs for disease, this title provides a detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. It exposes the disconnect between what society needs and what the drug companies are working on. Inhaltsverzeichnis ...

List of contents

00 - Introduction for the non-specialist
01 - Why there will be new drugs despite the ongoing 'crisis' of drug development in big pharma
02 - The need for medicine grows
03 - Medicines are becoming better
04 - Which diseases do we want to treat?
05 - Therapeutic Areas: strategically important diseases for the future
06 - Blockbuster proprietary drugs versus generic drugs
07 - Why is pharma a special industry?
08 - Diagnosing towards personalized medicine
09 - Personalized medicine
10 - How much can drugs cost?
11 - Modeling Drug Discovery until 2025
12 - Drug development models between 2010 and 2025

Report

"This book reviews in exquisite detail the drug development process from the initial inception of an idea through the life cycle of a new drug entity. The authors also spend an appropriate amount of time on the role of government-funded research programs along with the role of medium and small biotechnology companies in the drug treatment of diseases.Summing Up: Highly recommended." --CHOICE Reviews Online, December 2013
"Bartfai and Lees describe the looming crisis in health care.They target society in general as their audience, because of the need for the public to understand what is happening and why they should be concerned. The book is a compendium of data and analysis and there are many tables and figures supporting the text." --Reference and Research Book News, August 2013
"A remarkable compendium of hard data and wise prescription for the pharmaceutical industry." --Michael S. Brown, 1985 Novel Laureate in Medicine or Physiology, UT Southwestern Medical Center
"This is an extraordinary, insightful and provocative book that should be read by all those concerned by the progress of biomedicine, from scientists to politicians." --Jean-Pierre Changeux, Collège de France and l'Institut Pasteur
"Bartfai and Lees raise critical issues confronting the search for new medicines. Their analysis is cogent, and their proposals thoughtful and thought provoking. For anyone curious about where new medicines come from, and what it will take for the BioPharma industry to bring new treatments to patients with Alzheimer's disease, diabetes, depression, cancer, and more, this is a must read." --Michael D. Ehlers, Senior VP Pfizer and CSO Neuroscience, former Howard Hughes Investigator, Duke University
"This book is a must read for students, prescribing physicians, academic and industry researchers, analysts, patient groups, business and science journalists, and importantly, Policy Makers. More than ever before, drug development is a complex scientific, industrial and societal endeavour that needs the combined attention of Governments, Academics and Big Pharma; it cannot be left to Wall Street alone." --Daniel Hoyer, Chair, Department of Pharmacology, University of Melbourne, former Novartis Leading Scientist

Product details

• Authors: Dr. Tamas Bartfai, Tamas Bartfai, Tamas/ Lees Bartfai, BARTFAI TAMAS LEES GRAHAM V, Graham V. Lees, Graham V Lees, Graham V. Lees
• Publisher: Academic Press London
• Languages: English
• Product format: Paperback / Softback
• Released: 01.05.2013
• EAN: 9780124071803
• ISBN: 978-0-12-407180-3
• No. of pages: 328
• Series: Academic Press
• Subjects: Natural sciences, medicine, IT, technology > Medicine > Pharmacy; Social sciences, law, business > Business > Individual industrial sectors, branches; BUSINESS & ECONOMICS / Industries / Manufacturing, Manufacturing industries, Pharmaceutical industries